Clinical trials: Active Acne
Wrinkles, Fine Lines
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
The intended use of the Potenza™ device is to collect clinical data for brow lifting and/or treatment of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.
- Conditions
- Wrinkles, Fine Lines, Crepey Skin, Acne Scars
- Trial name
- NCT05254210
- Testing
- RF Device (Potenza™)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cynosure, Inc.
Acne Vulgaris
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl…
- Trial name
- NCT02005666
- Testing
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel
- Where
- 36 sites in United States, India
- Volunteers
- 850 people
- Sponsor
- Zydus Lifesciences Limited
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the therapeutic equivalence and safety of Tazarotene Cream 0.1% and Tazorac® (tazarotene cream 0.1%).
- Trial name
- NCT02411955
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Volunteers
- 1,077 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of…
- Trial name
- NCT02661958
- Testing
- S6G5T-3, S6G5T-1, S6G5T-5
- Where
- 34 sites in United States
- Volunteers
- 726 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris, Acne
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel, Tretinoin Gel and Vehicle Gel for the treatment of…
- Trial name
- NCT00689117
- Testing
- CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin)
- Where
- 32 sites in United States, Belize and 1 more
- Volunteers
- 1,649 people
- Sponsor
- Stiefel, a GSK Company
MILD TO SEVERE ACNE VULGARIS
Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01257906
- Testing
- CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL, ZIANA®, Vehicle Control
- Where
- India
- Volunteers
- 1,225 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Therapeutic equivalence and safety study
- Trial name
- NCT02929719
- Testing
- Test., Aczone Gel 5%
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of…
- Trial name
- NCT06673641
- Testing
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Acne Vulgaris
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
- Trial name
- NCT04015375
- Testing
- Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
- Where
- 13 sites in United States, Belize
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.
- Trial name
- NCT03427554
- Testing
- Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
- Where
- United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that : CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects CD0271…
- Trial name
- NCT01880320
- Testing
- CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
- Where
- 31 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
The objective of this study is to evaluate the therapeutic equivalence and safety of Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel (Taro Pharmaceuticals Inc.) and Epiduo® (Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel) (Galderma…
- Trial name
- NCT01742637
- Testing
- Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%, Epiduo® Gel
- Volunteers
- 2,008 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel
The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.
- Trial name
- NCT01188538
- Testing
- Epiduo gel, BPO
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Acne Treatment With Active Oplon's Patches - 15-18 Years Old
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.
- Trial name
- NCT01260766
- Testing
- Oplon Active Patch
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Oplon-Pure Science Ltd.
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
- Trial name
- NCT06063473
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
- Where
- United States
- Volunteers
- 762 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.
- Trial name
- NCT04883736
- Testing
- Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%
- Where
- United States
- Volunteers
- 973 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne
Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne
Study to evaluate the anti-acne efficacy of a dermo-cosmetic associated with the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment and to demonstrate that the dermo-cosmetic product can improve the local tolerance…
- Trial name
- NCT03832647
- Testing
- Epiduo, Salicylic Acid, Hydréane légère
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Vichy Laboratoires
Acne Vulgaris
Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris
Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel marketed by Valeant Pharmaceuticals, North America, is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01788384
- Testing
- Clindamycin Phosphate / Benzoyl Peroxide Gel, Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
- Volunteers
- 708 people
- Sponsor
- Watson Laboratories, Inc.
Acne Vulgaris
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
- Trial name
- NCT04797793
- Testing
- Adapalene Gel 0.1%, Differin® Gel (Adapalene 0.1%, Galderma)
- Where
- United States
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.